SCI Cancer Clinical Trials Office Blog

News & Updates from the SCI-CCTO
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
  • Cancer Clinical Trials Office
  • Stanford Cancer Institute

Service Correction for CTRU Studies relevant to July 1, 2017 – March 7, 2018

May 31, 2018 - SCI Communications

Effective March 7, 2018, the Clinical & Translational Research Unit has corrected the service description for service line items ‘CM001’ and ‘I-CM001’ | “Infusion time, base” for both non-industry and industry studies to reflect that is does not include “IV Placement/Central Line Access”. All studies requiring infusions must also include ‘CG003’ or ‘I-CG003’ into their budgets, as they will be invoiced for IV placements/Central Line Access. Studies that were approved and/or activated in the CTRU budget builder website between July 1, 2017 and March 7, 2018 will not be billed for service line item ‘CG003’ or ‘I-CG003’ through the entirety of those specific research projects. This will be voided if the study rebudgets for any of the reasons covered in the CTRU Subsidy and Cost Recovery Policy 2017.

This does not apply to studies:

  1. Approved and/or activated prior to July 1, 2017 and not submitted through the CTRU Budget Builder website.
  2. Approved and/or activated after March 7, 2018

For questions and requests, please contact ctru-notify@stanford.edu and the team will be happy to assist you.

Blog Submissions

If you have an announcement for the blog, please complete the Comms Request Form.

Reminder: Please have your blog post submitted to us by noon on Wednesday in order to have your post featured in the weekly email digest on Friday morning.

Archives

Categories

  • Announcements
  • Clinical Trials
  • Coordinator Corner
  • Educational Training
  • Events
  • Intake Process
  • IRB Updates
  • kudos
  • OnCore
  • Quality Corner
  • Regulatory Updates
  • Remote Monitoring
  • SCI Messages
  • Scientific Review Committee (SRC)
  • SOP/Guideline Updates
  • Staff Updates
  • Uncategorized
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube